# SLSN earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SLSN) · [Earnings tab](https://www.lopjlb.com/stock/SLSN?tab=earnings)

Updated: 2026-08-19T06:34:56

Quarters analyzed: 8

## Cross-quarter narrative

Across the eight earnings calls, Solesence’s story shifted from early‑stage growth optimism to a more cautious operational focus. In Q2 2024 the company highlighted strong demand, record‑setting revenue growth and on‑track capacity expansions, yet flagged margin pressure from a $500k write‑down and OTIF shortfalls. By Q3 2024 the order book remained robust and gross margins began edging toward 40%, but analysts warned of seasonality, supply‑chain concentration and the ability to sustain capacity utilization. The Q4 2024 release confirmed a record year, a modest margin expansion to 31% and a NASDAQ uplisting plan, while still noting limited second‑half visibility. The 2025 Q3 call revealed a 14% revenue decline, persistent margin compression to 23% and operational challenges around product design, labor efficiency and inventory control, prompting new initiatives such as facility consolidation and a unified Innovation group. The 2026 Q1 update showed modest margin recovery to 26% and progress on the Transform‑and‑Transcend program, but OTIF delays and supply‑chain alignment issues continued to pressure revenue conversion. Overall, demand remains solid on paper, but execution risk, margin volatility and visibility constraints have become the dominant themes.

## Latest CallCard · Q1

Solesence Q1 revenue fell to $13M on OTIF shipment delays; gross margin improved 300bps to 26%; Transform and Transcend initiative progressing with new tech launches and operational changes; $47M shipped/open orders; guidance maintained.

**Guidance:** maintained — Reiterated 30% gross margin floor and double-digit EBITDA margins by year-end; $47M shipped/open orders aligned with expectations.

**Tone:** mgmt 0.3 · Q&A pressure 0.4 · divergence 0.2

Management acknowledges Q1 challenges but highlights progress on 3 of 4 Transform and Transcend pillars, gross margin improvement, new proprietary technology launches, and reiterated full-year guidance.

### Demand visibility

Shipped and open orders at $47M; booking trends encouraging but normalized revenue environment expected.

Q1 revenue $13M vs $14.6M prior year due to OTIF shipment delays; $47M shipped/open orders includes shipped YTD and open orders for delivery within year; management sees continued excitement in SPF-infused beauty and new technologies.

### Margins / costs

Gross margin improved 300bps to 26% on labor efficiency and waste reduction; near-term EBITDA pressure from operational investments.

Gross margin 26% vs 23% prior year; improved labor efficiency and elimination of quality-related waste; adjusted EBITDA loss $107K vs +$609K prior year due to shift structure changes and lean manufacturing training; targeting double-digit EBITDA margins by year-end with labor efficiency gains and facility consolidation savings.

### Capital allocation

Investing in operational infrastructure (shift structure, training, SIOP) and facility consolidation; prioritizing Transform and Transcend execution.

Near-term investments in updated shift structure, lean manufacturing training, SIOP implementation, procurement and working capital discipline; expecting 6-figure annual savings from facility consolidation; no mention of dividends, buybacks, or M&A.

### Milestones

- **Transform and Transcend Initiative** [on_track]: Multiyear initiative to transform operational execution; early stages with progress on 3 of 4 pillars.
- **Pillar 1: Operational Excellence** [on_track]: Gross margin improvement and reduced inventory levels demonstrated in Q1.
- **Pillar 2: IP Leverage / New Tech Launches** [delivered]: Launched Chromalum and WHSPR proprietary technologies for SPF-infused hybrid products.
- **Pillar 3: Service Model Evolution** [on_track]: Completed 4 co-marketing activations with brands including Color Science, BloomAX, and Seal.
- **SIOP Implementation** [on_track]: Substantial improvements seen exiting Q1 into Q2 for inventory management and manufacturing preparation.
- **Facility Consolidation** [on_track]: Expecting 6-figure annual savings; part of path to double-digit EBITDA margins.
- **Shift Structure Update** [delivered]: Implemented updated shift structure in Q1 to address extended process changeovers and downtime.
- **Lean Manufacturing Training** [delivered]: Invested in training personnel in new lean manufacturing structure during Q1.

### Fears / risks

- **OTIF / Shipment Execution**: Soft OTIF performance delayed shipments in Q1, impacting revenue; dependent on SIOP process improvements
- **Revenue Normalization**: Guided for normalized revenue environment in 2026; booked and open orders $47M but conversion dependent on execution
- **Operational Transformation Execution**: Transform and Transcend multiyear initiative carries execution risk; near-term profitability pressure from investments
- **Supply Chain Alignment**: Raw material and componentry alignment issues caused shipment delays early in quarter
- **Margin Sustainability**: Gross margin improvement early stage; double-digit EBITDA margin target by year-end relies on labor efficiency gains and facility consolidation savings
- **Customer Concentration / Order Cancellation**: Risk of customer cancellation of purchase orders or supply agreements mentioned in safe harbor
- **Competitive Technology**: Impact of competitive products and technology noted in forward-looking statements

### Key quotes

> “Transform and Transcend is our structured multiyear initiative designed to transform our operational execution to transcend beyond the traditional CDMO model into a strategic supply side innovation partner that drives superior financial”

> “We are reiterating our previously communicated guidance for the year in which we established a 30% floor for gross profit margins and we remain on track to return to double-digit EBITDA margins by the end of the year as we realize”

> “Yesterday, we announced the launch of 2 new proprietary technologies, Chromalum and WHSPR. These technologies build on our existing platform and enable us to develop SPF-infused hybrid products for our brand partners that combine UV”

> “We had guided in Q4 that we thought this was a year and still believe this is a year of rationalized performance relative to revenue”

## Quarter one-liners

- **2026 Q1:** Solesence Q1 revenue fell to $13M on OTIF shipment delays; gross margin improved 300bps to 26%; Transform and Transcend initiative progressing with new tech launches and operational changes; $47M shipped/open orders; guidance maintained.
- **2025 Q4:** —
- **2025 Q3:** Revenue fell 14% YoY as the company confronts product design, labor efficiency and inventory control challenges, while management remains optimistic about SPF‑infused mineral beauty growth and operational improvements.
- **2025 Q1:** —
- **2024 Q4:** Solesence reports record 2024 revenue of $52.3M (+40% YoY), full-year net income of $4.2M, gross margin expansion to 31%, and plans NASDAQ uplisting in 2025 while citing strong demand but limited second-half visibility.
- **2024 Q3:** Nanophase posted record Q3 revenue and profit, highlighted operational throughput gains and strong order book, while noting limited full‑year guidance and ongoing focus on capacity, margins and supply‑chain diversification.
- **2024 Q2:** Nanophase posted a strong Q2 with $13M revenue and 32% growth, reaffirmed a record‑year goal, highlighted inventory and supply‑chain upgrades, and fielded analyst concerns on margins, staffing and uplisting.
- **2024 Q1:** —

## Theme arcs

- **Demand strength** (deteriorating): Early calls reported strong order flow and record shipments; later calls show revenue decline and limited visibility despite sizable order backlog.
- **Gross margin pressure** (deteriorating): Margins expanded to 31% in 2024 then fell to 23% in 2025 Q3 before modestly improving to 26% in 2026 Q1.
- **Operational execution** (improving): Initial capacity and OEE initiatives were on‑track; later calls introduced Transform‑and‑Transcend and facility consolidation to address execution gaps.
- **Supply‑chain risk** (stable): Write‑down and component obsolescence flagged in 2024, diversification efforts noted, but raw‑material alignment issues re‑emerged in 2026 Q1.
- **Visibility and guidance** (stable): Management consistently offered vague guidance and highlighted limited second‑half visibility across calls.
- **Capital investment** (stable): Capex funded from operations (≈$3‑6M) persisted, with ongoing facility expansions and automation projects.
- **NASDAQ uplisting ambition** (new): Announced in 2024 Q4 with CFO search and continued pursuit in 2025‑2026.
- **Labor efficiency** (improving): Early concerns gave way to targeted OEE gains and labor‑per‑unit reductions in 2025‑2026 initiatives.
- **Inventory control** (deteriorating): Write‑down in 2024 and ongoing control improvements still not fully realized by 2025‑2026.

## Fear persistence

- **Supply‑chain risk** [recurring]: Obsolete inventory write‑down (2024 Q2) and raw‑material alignment issues (2026 Q1).
- **Margin pressure** [recurring]: Consistent concerns from 2024 Q2 through 2026 Q1 about achieving 40% gross margin.
- **OTIF / shipment execution** [recurring]: Below‑target OTIF noted in 2024 Q2, 2024 Q3 and delays in 2026 Q1.
- **Visibility and order uncertainty** [recurring]: Limited second‑half visibility cited in multiple calls.
- **Cash constraints** [resolved]: Cash balance limitation highlighted in 2024 Q2 but not mentioned thereafter.
- **Industry slowdown** [new]: General consumer softening noted in 2025 Q3.

## Guidance path

2024 Q1:vague → 2024 Q2:maintained → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:maintained

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SLSN`